Zimbabwe is now one of the first countries in the world to start a lenacapavir program, which was made possible through funding from the United States government and The Global Fund.

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

Researchers evaluated the association between the use of various hormonal contraceptives and the risk for surgically treated intracranial meningioma.

Zimbabwe is one of the first countries to introduce the HIV prevention drug lenacapavir. The program aims to target over 46,000 high-risk individuals, backed by U.S. funding and the Global Fund.

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the country one of the first globally to roll it out as the southern African ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

In the heart of Mississippi, Diana "Di" Fillhart, a vibrant 68-year-old, lives a life defined by purpose and an unwavering ...

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...

Dr. Dan Thomson shares essential tips for injections, needle selection and syringe maintenance to ensure herd health and ...

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...